Li Du, Fred Deiter, Mohamed S Bouzidi, Jean-Noël Billaud, Graham Simmons, Prerna Dabral, Suganya Selvarajah, Anuradha F Lingappa, Maya Michon, Shao Feng Yu, Kumar Paulvannan, Balaji Manicassamy, Vishwanath R Lingappa, Homer Boushey, John R Greenland, Satish K Pillai
The ongoing evolution of SARS-CoV-2 to evade vaccines and therapeutics underlines the need for innovative therapies with high genetic barriers to resistance. Therefore, there is pronounced interest in identifying new pharmacological targets in the SARS-CoV-2 viral life cycle. The small molecule PAV-104, identified through a cell-free protein synthesis and assembly screen, was recently shown to target host protein assembly machinery in a manner specific to viral assembly. In this study, we investigate the capacity of PAV-104 to inhibit SARS-CoV-2 replication in human airway epithelial cells (AECs)...
April 22, 2024: Communications Biology